Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms MOBILE
- Sponsors Roche
- 10 Jun 2016 New trial record